EP1299362A4 - Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci - Google Patents
Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ciInfo
- Publication number
- EP1299362A4 EP1299362A4 EP01952440A EP01952440A EP1299362A4 EP 1299362 A4 EP1299362 A4 EP 1299362A4 EP 01952440 A EP01952440 A EP 01952440A EP 01952440 A EP01952440 A EP 01952440A EP 1299362 A4 EP1299362 A4 EP 1299362A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- mch1
- receptor antagonists
- concentrating hormone
- melanin concentrating
- selective melanin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/79—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US610213 | 1990-11-06 | ||
US61021300A | 2000-07-05 | 2000-07-05 | |
PCT/US2001/021286 WO2002006245A1 (fr) | 2000-07-05 | 2001-07-05 | Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1299362A1 EP1299362A1 (fr) | 2003-04-09 |
EP1299362A4 true EP1299362A4 (fr) | 2004-11-03 |
Family
ID=24444133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01952440A Withdrawn EP1299362A4 (fr) | 2000-07-05 | 2001-07-05 | Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1299362A4 (fr) |
JP (1) | JP2004504303A (fr) |
AU (1) | AU783403B2 (fr) |
CA (1) | CA2384041A1 (fr) |
WO (1) | WO2002006245A1 (fr) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
JP2004516239A (ja) | 2000-07-06 | 2004-06-03 | ニューロジェン コーポレイション | メラニン凝集ホルモン受容体リガンド |
US6809104B2 (en) | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
CA2446351A1 (fr) | 2001-05-04 | 2002-11-14 | Tularik Inc. | Composes heterocycliques fondus |
CA2448080A1 (fr) | 2001-05-22 | 2002-11-28 | Neurogen Corporation | Ligands recepteurs de l'hormone de concentration de la melanine: analogues de 1-benzyl-4-aryl piperazine substituee |
US7199135B2 (en) | 2001-07-05 | 2007-04-03 | H. Lundbeck A/S | Substituted alkyl amido piperidines |
US7105544B2 (en) | 2001-07-05 | 2006-09-12 | Synaptic Pharmaceutical Corporation | Substituted alkyl amido piperidines |
JP2005519876A (ja) | 2001-11-27 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | 2−アミノキノリン化合物 |
WO2003059289A2 (fr) | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Ligands recepteurs de l'hormone de concentration de la melanine: analogues de benzoimidazole substitue |
CA2473236A1 (fr) | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Ligands recepteurs de l'hormone de concentration de la melanine: 2-(4-benzyl-piperazine-1-ylmethyl)- substitue et analogues de 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole |
US6818772B2 (en) | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
WO2003070244A1 (fr) * | 2002-02-22 | 2003-08-28 | Abbott Laboratories | Antagoniste des effets d'une hormone de concentration de melanine et son utilisation |
TW200401777A (en) * | 2002-06-27 | 2004-02-01 | Schering Corp | Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
UA77536C2 (en) | 2002-07-03 | 2006-12-15 | Lundbeck & Co As H | Secondary aminoaniline piperidines as mch1 antagonists and their use |
UA77814C2 (en) | 2002-07-03 | 2007-01-15 | Lundbeck & Co As H | Spirocyclic piperidines as antagonists of mch1 and use thereof |
DE10238865A1 (de) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US7045527B2 (en) | 2002-09-24 | 2006-05-16 | Amgen Inc. | Piperidine derivatives |
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
DE10250743A1 (de) * | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
AU2003285160B2 (en) | 2002-11-06 | 2009-06-04 | Amgen Inc. | Fused heterocyclic compounds |
KR20050085115A (ko) | 2002-11-22 | 2005-08-29 | 스미스클라인 비참 코포레이션 | 신규 화합물 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2004069798A1 (fr) | 2003-02-10 | 2004-08-19 | Banyu Pharmaceutical Co.,Ltd. | Antagonistes des recepteurs de l'hormone concentrant la melanine contenant des derives de piperidine en tant que principe actif |
JP4630555B2 (ja) * | 2003-02-12 | 2011-02-09 | 武田薬品工業株式会社 | アミン誘導体 |
US7601868B2 (en) | 2003-02-12 | 2009-10-13 | Takeda Pharmaceutical Company Limited | Amine derivative |
DE602004013427T2 (de) * | 2003-02-28 | 2009-06-04 | Schering Corp. | Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen |
WO2004080411A2 (fr) | 2003-03-07 | 2004-09-23 | Neurocrine Biosciences, Inc. | Antagonistes du recepteur de l'hormone concentrant la melanine et compositions et methodes associees |
US20060194871A1 (en) * | 2003-04-11 | 2006-08-31 | Barvian Kevin K | Heterocyclic mchr1 antagoists |
US7157461B2 (en) | 2003-07-23 | 2007-01-02 | Bristol-Myers Squibb Co. | Substituted dihydropyrimidine inhibitors of calcium channel function |
US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
WO2005028438A1 (fr) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de piperidine |
US20050176738A1 (en) * | 2003-11-07 | 2005-08-11 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
US7241787B2 (en) | 2004-01-25 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments |
US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
US7732456B2 (en) | 2004-03-05 | 2010-06-08 | Banyu Pharmaceutical Co., Ltd. | Pyridone derivative |
WO2005097127A2 (fr) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques |
US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE102004017934A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CN101094689B (zh) | 2004-11-01 | 2013-06-12 | 安米林药品有限责任公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
US7737155B2 (en) * | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
JP4975739B2 (ja) * | 2005-05-17 | 2012-07-11 | シェーリング コーポレイション | 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環 |
US8138206B2 (en) | 2005-05-30 | 2012-03-20 | Msd. K.K. | Piperidine derivative |
TW200716580A (en) | 2005-06-08 | 2007-05-01 | Smithkline Beecham Corp | (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one |
JPWO2007018248A1 (ja) | 2005-08-10 | 2009-02-19 | 萬有製薬株式会社 | ピリドン化合物 |
EP1922336B1 (fr) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Polypeptides hybrides presentant des proprietes selectionnables |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
DE602006017712D1 (de) | 2005-08-24 | 2010-12-02 | Banyu Pharma Co Ltd | Phenylpyridonderivat |
US20090264426A1 (en) | 2005-09-07 | 2009-10-22 | Shunji Sakuraba | Bicyclic aromatic substituted pyridone derivative |
CA2624030A1 (fr) | 2005-09-29 | 2007-04-12 | Tianying Jian | Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4 |
EP2332526A3 (fr) | 2005-10-21 | 2011-10-12 | Novartis AG | combinaison d'un inhibiteur de rénine avec un agent anti-dyslipidémique ou un agent anti-obèse |
CA2627139A1 (fr) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de benzoxathiine |
EP1953165B1 (fr) | 2005-11-10 | 2012-02-01 | Msd K.K. | Derive spiro aza-substitue |
KR20080094699A (ko) | 2006-02-15 | 2008-10-23 | 사노피-아벤티스 | 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도 |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
CA2664113C (fr) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Utilisation de la platencine et de la platensimycine en tant qu'inhibiteurs de la synthese des acides gras pour traiter l'obesite, lediabete et le cancer |
EP2072519A4 (fr) | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | Dérivé de diarylcétimine |
WO2008120653A1 (fr) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Dérivé d'indoledione |
EP2998314B1 (fr) | 2007-06-04 | 2020-01-22 | Bausch Health Ireland Limited | Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
PE20091309A1 (es) * | 2007-12-21 | 2009-09-30 | Astrazeneca Ab | Derivados de ciclohexilo como inhibidores de acetil coenzima a carboxilasa |
EP2264026A4 (fr) | 2008-03-06 | 2012-03-28 | Msd Kk | Dérivé d'alkylaminopyridine |
CN101981025A (zh) | 2008-03-28 | 2011-02-23 | 万有制药株式会社 | 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物 |
WO2009149279A2 (fr) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
EP2301936A1 (fr) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Dérivé de spirodiamine-diarylcétoxime |
WO2010003624A2 (fr) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation |
WO2010009319A2 (fr) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres |
US20110124674A1 (en) | 2008-07-30 | 2011-05-26 | Hiroyuki Kishino | 5/5-or 5/6-membered condensed ring cycloalkylamine derivative |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
PE20110852A1 (es) | 2008-10-30 | 2011-11-25 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida |
JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
EP2379547A1 (fr) | 2008-12-16 | 2011-10-26 | Schering Corporation | Dérivés de pyridopyrimidine et leurs procédés d'utilisation |
EP2379562A1 (fr) | 2008-12-16 | 2011-10-26 | Schering Corporation | Dérivés de pyranone bicyclique comme agonistes du récepteur de l'acide nicotinique |
UY32443A (es) | 2009-02-13 | 2010-09-30 | Sanofi Aventis | Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento. |
AR075401A1 (es) | 2009-02-13 | 2011-03-30 | Sanofi Aventis | Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento |
WO2011023754A1 (fr) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, substances pharmaceutiques comprenant ces composés et leur utilisation |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
WO2012120055A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120054A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
EP2683698B1 (fr) | 2011-03-08 | 2017-10-04 | Sanofi | Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation |
WO2012120057A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation |
EP2683701B1 (fr) | 2011-03-08 | 2014-12-24 | Sanofi | Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation |
EP2683700B1 (fr) | 2011-03-08 | 2015-02-18 | Sanofi | Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
CA2853024C (fr) | 2011-11-11 | 2017-08-22 | Pfizer Inc. | 2-thiopyrimidinones |
WO2014022528A1 (fr) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
EP2970119B1 (fr) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
CN104098562A (zh) * | 2013-04-12 | 2014-10-15 | 苏州科捷生物医药有限公司 | 一种5,6-二氢吡啶[2,3-d]嘧啶-4,7(3H,8H)-二酮的合成方法 |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
US9708272B2 (en) | 2014-08-29 | 2017-07-18 | Tes Pharma S.R.L. | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase |
BR112017022340A2 (pt) | 2015-05-05 | 2018-07-10 | Pfizer | 2-tiopirimidinonas |
RU2019114228A (ru) | 2016-10-14 | 2020-11-16 | Тес Фарма С.Р.Л. | ИНГИБИТОРЫ ДЕКАРБОКСИЛАЗЫ ПОЛУАЛЬДЕГИДА α-АМИНО-β-КАРБОКСИМУКОНОВОЙ КИСЛОТЫ |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
EP3558298A4 (fr) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Composés de spirochromane antidiabétiques |
KR20210111248A (ko) | 2018-11-20 | 2021-09-10 | 테스 파마 에스.알.엘. | α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제 |
TW202045476A (zh) | 2019-02-13 | 2020-12-16 | 美商默沙東藥廠 | 5-烷基吡咯啶食慾素受體促效劑 |
KR20220066252A (ko) | 2019-07-11 | 2022-05-24 | 프락시스 프리시젼 메디신즈, 인크. | T형 칼슘 채널 조절제의 제형 및 이의 사용 방법 |
EP4010314B1 (fr) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle |
EP4076527A1 (fr) * | 2020-01-10 | 2022-10-26 | Consynance Therapeutics, Inc. | Polythérapies de médicaments et leurs méthodes d'utilisation |
WO2022040070A1 (fr) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de l'orexine de type bicycloheptane pyrrolidine |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0444546A1 (fr) * | 1990-02-23 | 1991-09-04 | Mochida Pharmaceutical Co., Ltd. | Dérivés de l'hydantoine pour l'utilisation comme agents hypoglycémiques et/ou hypolipidémiques |
WO1996014846A1 (fr) * | 1994-11-16 | 1996-05-23 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines et leurs utilisations |
WO1998003494A1 (fr) * | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Derives benzylamine a substitution amido et amino, et classe de ligands specifiques du neuropeptide y1 |
WO1998019998A2 (fr) * | 1996-11-07 | 1998-05-14 | Novartis Ag | 2-cyanopyrrolidines a substitution n |
WO1998033791A1 (fr) * | 1997-02-04 | 1998-08-06 | Bristol-Myers Squibb Company | Derives de dihydropyrimidone comme antagonistes du neuropeptide y (npy) |
WO1998051311A2 (fr) * | 1997-05-16 | 1998-11-19 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines et leurs utilisations |
EP0921125A1 (fr) * | 1997-12-05 | 1999-06-09 | F. Hoffmann-La Roche Ag | Derives de la 1,3,8-triazaspiro[4,5]decan-4-one |
WO2000006565A1 (fr) * | 1998-07-30 | 2000-02-10 | Merck & Co., Inc. | ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a |
WO2000025770A1 (fr) * | 1998-10-30 | 2000-05-11 | Merck & Co., Inc. | Inhibiteurs carbocycliques des canaux de potassium |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2253862A1 (fr) * | 1996-05-16 | 1997-11-20 | Wai C. Wong | Dihydropyrimidines et leurs emplois |
US6037354A (en) * | 1997-06-18 | 2000-03-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
-
2001
- 2001-07-05 JP JP2002512149A patent/JP2004504303A/ja not_active Withdrawn
- 2001-07-05 WO PCT/US2001/021286 patent/WO2002006245A1/fr not_active Application Discontinuation
- 2001-07-05 EP EP01952440A patent/EP1299362A4/fr not_active Withdrawn
- 2001-07-05 AU AU73192/01A patent/AU783403B2/en not_active Ceased
- 2001-07-05 CA CA002384041A patent/CA2384041A1/fr not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0444546A1 (fr) * | 1990-02-23 | 1991-09-04 | Mochida Pharmaceutical Co., Ltd. | Dérivés de l'hydantoine pour l'utilisation comme agents hypoglycémiques et/ou hypolipidémiques |
WO1996014846A1 (fr) * | 1994-11-16 | 1996-05-23 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines et leurs utilisations |
WO1998003494A1 (fr) * | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Derives benzylamine a substitution amido et amino, et classe de ligands specifiques du neuropeptide y1 |
WO1998019998A2 (fr) * | 1996-11-07 | 1998-05-14 | Novartis Ag | 2-cyanopyrrolidines a substitution n |
WO1998033791A1 (fr) * | 1997-02-04 | 1998-08-06 | Bristol-Myers Squibb Company | Derives de dihydropyrimidone comme antagonistes du neuropeptide y (npy) |
WO1998051311A2 (fr) * | 1997-05-16 | 1998-11-19 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines et leurs utilisations |
EP0921125A1 (fr) * | 1997-12-05 | 1999-06-09 | F. Hoffmann-La Roche Ag | Derives de la 1,3,8-triazaspiro[4,5]decan-4-one |
WO2000006565A1 (fr) * | 1998-07-30 | 2000-02-10 | Merck & Co., Inc. | ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a |
WO2000025770A1 (fr) * | 1998-10-30 | 2000-05-11 | Merck & Co., Inc. | Inhibiteurs carbocycliques des canaux de potassium |
Non-Patent Citations (4)
Also Published As
Publication number | Publication date |
---|---|
WO2002006245A1 (fr) | 2002-01-24 |
EP1299362A1 (fr) | 2003-04-09 |
JP2004504303A (ja) | 2004-02-12 |
CA2384041A1 (fr) | 2002-01-24 |
AU783403B2 (en) | 2005-10-20 |
AU7319201A (en) | 2002-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1299362A4 (fr) | Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci | |
EP1141020A4 (fr) | Adn codant un recepteur d'hormone (mch1) concentrant la melamine humaine et utilisations associees | |
HK1045308A1 (zh) | 選擇性神經激肽拮抗物 | |
GB0004138D0 (en) | Single trip perforate and gravel system | |
AU9684401A (en) | Hedgehog antagonists, methods and uses related thereto | |
AU2001229491A1 (en) | Cyclic peptides as potent and selective melanocortin-4 receptor antagonists | |
IL204486A0 (en) | Selective androgen receptor modulators and methods of uses thereof | |
EP1254116A4 (fr) | Antagonistes du recepteur de l'integrine alpha v | |
EP1418900A4 (fr) | Modulateurs des recepteurs d'oestrogene selectifs | |
EP1252162A4 (fr) | Antagonistes du recepteur de l'integrine alpha v | |
AU9259801A (en) | Alpha v integrin receptor antagonists | |
AU2002216079A1 (en) | Bombesin receptor antagonists | |
IL154654A0 (en) | Osteoclast-associated receptor | |
EP1351687A4 (fr) | Antagonistes des recepteurs de l'urotensine ii | |
HU0105260D0 (en) | Anchoring wedge | |
AU2002359524A8 (en) | P2x7 receptor antagonists | |
AU2002217095A1 (en) | Bombesin receptor antagonists | |
GB9820014D0 (en) | Receptor antagonists and uses thereof | |
AU2574801A (en) | Selective iGLUR5 receptor antagonists | |
AU1252102A (en) | Receptor | |
GB0000474D0 (en) | Receptor | |
AU9088401A (en) | Alpha v integrin receptor antagonists | |
GB0026327D0 (en) | Thrombin receptor antagonists | |
PL361462A1 (en) | Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a | |
PL345949A1 (en) | Novel angiotensin receptor, production and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020531 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CHIU, GEORGE Inventor name: NAGARATHNAM, DHANAPALAN Inventor name: NOBLE, STEWART Inventor name: GLUCHOWSKI, CHARLES Inventor name: DELEON, JOHN, E. Inventor name: MARZABADI, MOHAMMAD, R. Inventor name: WETZEL, JOHN Inventor name: LAGU, BHARAT |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 25/24 B Ipc: 7A 61P 25/22 B Ipc: 7A 61P 3/04 B Ipc: 7A 61K 31/427 B Ipc: 7A 61K 31/4192 B Ipc: 7A 61K 31/4188 B Ipc: 7A 61K 31/165 B Ipc: 7A 61K 31/505 B Ipc: 7C 07D 491/04 B Ipc: 7C 07D 239/22 B Ipc: 7C 07D 249/18 B Ipc: 7C 07D 471/10 B Ipc: 7C 07D 211/52 B Ipc: 7C 07D 471/04 B Ipc: 7C 07D 295/06 B Ipc: 7C 07D 417/06 B Ipc: 7C 07C 233/79 B Ipc: 7C 07D 401/14 B Ipc: 7C 07D 413/14 B Ipc: 7C 07D 211/58 B Ipc: 7C 07D 491/10 B Ipc: 7C 07D 401/12 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040921 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: H. LUNDBECK A/S |
|
17Q | First examination report despatched |
Effective date: 20050822 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070403 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1054550 Country of ref document: HK |